Study of Monitoring Exhaled NO in Symptomatic Asthmatic Adults and Children During Anti-inflammatory Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

151 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Study Completion Date

2007-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to demonstrate substantial equivalence between two medical devices which measure nitric oxide in exhaled breath, NIOX MINO® and NIOX® in Symptomatic Asthmatic Adults and Children.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Asthma is a chronic inflammatory disorder of the airways. Chronically inflamed airways are hyperresponsive; they become obstructed and airflow is limited (by bronchoconstriction, mucus plugs, and increased inflammation) when airways are exposed to various risk factors. Asthma causes recurring episodes of wheezing, breathlessness, chest tightness, and coughing particularly at night or in the early morning.

NO is an important endogenous regulatory molecule that is widely distributed throughout the body. The detection of NO in exhaled air was first reported in 1991, and, soon after it was shown that the levels NO in exhaled air are elevated in patients with asthma. There is now much evidence showing that measurement of the concentration of NO in exhaled air offers a useful non-invasive method of assessing inflammatory airway disease.

Exhaled NO is not increased during bronchospasm unless there is coexisting inflammation. Exhaled NO may have a valuable role in differentiating between the inflammatory and bronchospastic components of clinical asthma, and is also useful for guiding the therapeutic use of steroids and other anti-inflammatory agents.

A study on asthmatics and non-asthmatics subjects has shown that substantial equivalence exists between the stationary device NIOX® and the hand held device NIOX MINO® when comparing NO measurements, when similar conditions are considered and examinations are made as consistently as possible.

In a study with the stationary device NIOX®, exhaled NO was measured before and after two weeks of inhaled corticosteroid treatment in unstable steroid-naïve adult and paediatric asthmatic subjects. The result was a 50.5% mean reduction of exhaled NO. The change in exhaled NO was also compared to change in standard asthma outcome measures, asthma symptoms and spirometry.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The Aerocrine NIOX MINO® Airway Inflammation Monitor

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children, and adults.
* A history of physician-diagnosed asthma or asthma diagnosed by a physician.
* Spirometry performed parameters.
* An increased FENO value.
* Symptomatic asthma as defined on the Asthma Control Questionnaire® (ACQ).

Exclusion Criteria

* Use of oral corticosteroids.
* Use of intranasal corticosteroids.
* Use of non-steroidal anti-asthma drugs.
* Current serious conditions and/or therapies that are confounding factors.
* Pregnancy.
* Other significant respiratory diseases and/or cardiovascular diseases.
* Current participation in another interventional clinical study.
* Inability to comply with the study procedures, e.g. spirometry and FENO measurements according to standard procedures.
* Unwillingness to sign informed consent and comply with treatment and visits.
* Smoking within 6 months before the study, or a smoking history of \>10 pack years or an equivalent amount of other tobacco use.
* Known alcohol or drug abuser.
* Food and beverage (other than water) intake within 1 hour before first FENO measurement
* Nicotine (including nicotine chewing gum, nicotine patch, snuff etc) use within 1 hour before first FENO measurement.
* Strenuous exercise within 1 hour before first FENO measurement

Minimum Eligible Age

4 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Aerocrine AB

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Price, Professor

Role: STUDY_CHAIR

Dept of General Practice and Primary Care, University of Aberdeen

Sven-Erik Dahlén, Professor

Role: STUDY_CHAIR

Unit for Experimental Asthma and Allergy Research Division of Physiology, The National Institute of Environmental Medicine Karolinska Institutet

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Näsets Läkargrupp, Falsterbov. 79, SE-23651 Höllviken

Höllviken, , Sweden

Site Status

Department of General Practice & Primary Care University of Aberdeen

Aberdeen, , United Kingdom